NeoStem And Its Subsidiary, Progenitor Cell Therapy (PCT), To Present At Five Sessions At The 2014 Phacilitate Cell & Gene Therapy Forum

NEW YORK, Jan. 13, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), an internationally recognized contract development and manufacturing organization, announced today that NeoStem and PCT will present at five sessions at the Phacilitate Cell & Gene Therapy Forum 2014 in Washington DC.

Of particular note is the January 29 Breakfast Workshop hosted by PCT which will focus on PCT's Development by Design ("DbD") concept, aimed at helping PCT's clients methodically identify and address quality, cost, scale, and sustainability goals that are both challenging and critical for commercial-scale manufacture of cell therapy products.

"PCT's DbD methodology is designed to inform and accelerate the use of engineering principles and innovative solutions such as automation, integration, and closed system design, to provide a manufacturing process that will meet these commercial goals," said Brian Hampson, Senior Director, Engineering & Innovation services at PCT, and leader of the Workshop. "DbD provides a systems approach to guide strategy for manufacturing development and can be applied across the full range of cell-based therapeutic products."

The Company's other presentations range in topic from business to product characterization assays and a case study on CD34+ bone marrow stem cells in interventional cardiology.

"We are proud to showcase the depth and breadth of our resources at Phacilitate," Dr. Robert A. Preti, Chief Scientific Officer of PCT and NeoStem and President of PCT, "and demonstrate how PCT can provide solutions that help our clients achieve their cell therapy development and commercialization goals."

Phacilitate Cell & Gene Therapy Forum 2014 January 27-29, 2014 Grand Hyatt, Washington, DC

Monday, January 27, 2014

Session #1: Cell & Gene Therapy Business
  • Time: 9:00 AM EST
  • Speaker: Robert A. Preti, PhD, Chief Scientific Officer and President of PCT

Session #2: Product characterization assays – what are they good for?
  • Time: 12:25 PM EST
  • Speaker:Timothy Fong, PhD, MBA, Vice President, Technology &Product Development, PCT

Tuesday, January 28, 2014

Session: Challenges and future directions for commercial scale manufacturing
  • Time: 3:00 PM EST
  • Speaker: Brian Hampson, MS, Senior Director, Engineering & Innovation of PCT

Wednesday, January 29, 2014

Session #1: Development by Design (DbD) – A model for managing comparability risks and optimizing process development for Cell Therapy and Immunotherapy processes (Breakfast Workshop Hosted by PCT)
  • Time: 7:45 AM EST
  • Workshop leader: Brian Hampson, MS, Senior Director, Engineering & Innovation of PCT

Session #2: Case Study – CD34+ bone marrow stem cells: nature's blueprint for interventional cardiology
  • Time: 12:40 PM EST
  • Speaker: Jonathan Sackner-Bernstein, MD, FACC, Vice President, Clinical Development of NeoStem

About NeoStem, Inc.

NeoStem, Inc. is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

If you liked this article you might like

Neostem (NBS) Stock Declines After Pricing Secondary Public Offering

3 Breakout Stocks Under $10 for Your Trading Radar

Insider Trading Alert - UGI, NBS And MACK Traded By Insiders

Neostem (NBS): Today's Weak On High Volume Stock

NeoStem (NBS) Stock Plummets Today on Disappointing Cardiac Stem-Cell Therapy Data